What Doctors Are Learning About GLP-1s and Male Fertility

When millions of men started taking GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound for weight loss and diabetes, a question kept coming up in clinics: what does this do to my hormones, my testosterone, and my fertility?

The concern wasn't unreasonable. Any drug that changes body composition substantially has hormonal effects. Men in their 30s, 40s, and 50s, the heaviest GLP-1 users by demographics, are also the population most likely to think about fertility for themselves or future children, and most likely to be considering testosterone replacement therapy if they have low energy or low libido.

The fear was straightforward: would GLP-1s lower testosterone or otherwise harm male reproductive function in ways that could make obesity-related fertility problems worse?

The new data goes in a different direction.

Testosterone is the main male sex hormone. It's produced primarily by the testes, with a small amount from the adrenal glands. The brain controls production through a feedback loop: the hypothalamus releases GnRH (gonadotropin-releasing hormone), which tells the pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone), which together tell the testes to make testosterone and produce sperm.

Healthy adult male testosterone levels typically run between 300 and 1,000 nanograms per deciliter (ng/dL) of blood. Levels below 300 ng/dL combined with symptoms (low energy, low libido, depressed mood, reduced muscle mass) are classified as low testosterone, or hypogonadism. About 20% of men over 60 meet that definition, but the prevalence among younger men with obesity is rising fast.

Three things commonly go together: obesity, low testosterone, and reduced fertility. Body fat actively converts testosterone to estrogen through an enzyme called aromatase, which means that men with more body fat tend to have lower testosterone and higher estrogen than leaner men of the same age. The estrogen feeds back to the brain, telling it to make less GnRH, which lowers LH and FSH, which lowers testosterone further. The cycle becomes self-reinforcing.

Among men with obesity, low testosterone shows up in 40% to 50% of cases, much higher than in the general population. The standard medical treatment for low testosterone is testosterone replacement therapy, or TRT, which gives men back the testosterone their bodies aren't making enough of.

TRT works for symptom relief. Energy returns. Libido improves. Muscle mass rebuilds. But TRT has a major catch for men who want to have children. When you add outside testosterone to the body, the brain detects the increased levels and shuts down its own production signals. LH and FSH drop. The testes stop making their own testosterone, and they stop producing sperm.

This is why TRT is sometimes called a fertility off switch. Men who go on TRT during their reproductive years and want to father children later face an uncomfortable trade-off: fix the symptoms now and risk infertility, or live with the symptoms and preserve sperm production. The standard workarounds (HCG injections, clomiphene) work imperfectly and are not always covered by insurance.

So when GLP-1 drugs came along and started causing significant weight loss in men with obesity-related low testosterone, doctors and researchers got curious. Would the same weight loss that comes with these drugs also restore natural testosterone production? Or would the rapid metabolic changes throw something else off?

On June 14, 2026, a research team from University Hospitals Coventry and Warwickshire and Warwick Medical School in the United Kingdom presented data at the Endocrine Society's annual meeting in Chicago that addressed the question head-on. Principal investigator Pratibha Natesh and colleagues conducted a meta-analysis of randomized controlled trials of GLP-1 medications in men aged 18 to 65 with obesity-related low testosterone.

The results pointed the opposite direction from what TRT-style suppression would predict. After 24 weeks of GLP-1 treatment, men in the pooled trials showed:

• Improved testosterone levels
• Higher sperm count
• Better sperm shape and motility

Natesh's team pointed to two likely mechanisms. The first is the obesity-testosterone cycle running in reverse. As men lose fat on GLP-1s, less testosterone gets converted to estrogen via aromatase, and the brain restores normal GnRH signaling, which restarts LH and FSH production, which restarts testosterone production by the testes themselves. The cycle that was suppressing them flips.

The second mechanism is that GLP-1s may directly reduce systemic inflammation and metabolic stress, both of which independently suppress testosterone production. Inflammation in the testes themselves can damage sperm production. Obesity is a chronic low-grade inflammatory state. GLP-1 drugs may dampen that signal.

If the Natesh team's findings hold up in more research, the practical implication for men is significant. The standard treatment path for obesity-related low testosterone has been TRT, which fixes symptoms but suppresses fertility. A GLP-1 drug that addresses the same problem (low testosterone in men with obesity) by triggering natural testosterone recovery rather than replacing testosterone externally would preserve fertility instead of shutting it down.

That doesn't mean GLP-1s will replace TRT. Some men have low testosterone for reasons that have nothing to do with obesity: primary hypogonadism from testicular damage, Klinefelter syndrome, certain medications, and age-related decline among them. For those men, the obesity-testosterone cycle isn't the underlying driver, so weight loss alone won't fix the problem. TRT remains the right answer.

But for the substantial population of men whose low testosterone is tied to excess weight, the order of treatment may shift. Try weight loss on a GLP-1 first. See if natural testosterone recovers. If it does, you avoid TRT entirely. If it doesn't recover enough, you can layer TRT on a leaner body and likely need a smaller dose.

The fertility angle matters most for men in their 20s, 30s, and early 40s who haven't completed their families. For older men past child-rearing years, the fertility difference between GLP-1 and TRT carries less weight, and TRT may still be the faster symptom fix.

The Natesh team's data is preliminary in several ways.

The meta-analysis pooled trials of varying sizes and designs. Most of the underlying trials were not designed primarily to study male reproductive endpoints; testosterone and sperm parameters were secondary outcomes. The patient populations studied were specifically men with high BMI and obesity-related low testosterone, so external validity to normal-weight men or to men whose low testosterone has a non-obesity cause is unproven. And 24 weeks is a relatively short follow-up for fertility outcomes; longer studies are needed to know whether the improvements persist or whether they plateau.

There's also a question about which GLP-1 works best. The Natesh meta-analysis pooled different agents (semaglutide, liraglutide, dulaglutide), and the effect sizes varied across studies. Tirzepatide, the newer dual GIP/GLP-1 agonist, may behave differently because GIP signaling has its own effects on fat tissue and inflammation. The forthcoming generation of triple agonists (retatrutide) and amylin analogs (petrelintide) will need their own male-fertility data before recommendations can be made for those classes.

For high school readers paying attention to medicine, the story so far is that one of the most worried-about side effects of GLP-1 drugs in men appears to run in the opposite direction. The fertility-preserving angle could become the deciding factor for men in their reproductive years choosing between GLP-1 weight loss and TRT, though the field still needs longer trials, more head-to-head comparisons, and dedicated fertility endpoints before this becomes a definitive recommendation.